In:
Neuropsychobiology, S. Karger AG, Vol. 39, No. 1 ( 1999), p. 25-32
Abstract:
Amisulpride, a selective antagonist for D 〈 sub 〉 2 〈 /sub 〉 and D 〈 sub 〉 3 〈 /sub 〉 dopamine receptors, acts preferentially on presynaptic receptors increasing dopaminergic transmission at low doses. In a multicentre, 3-month, placebo-controlled study, amisulpride (50 mg/day) was compared to amineptine (200 mg/day) in the treatment of primary dysthymia. A total of 323 patients were enrolled. Amisulpride and amineptine were found to be statistically superior to placebo (p 〈 0.0001) on the Clinical Global Impression (item 2): 63, 64 and 33% responders, respectively; improvement of Montgomery-Asberg Depression Rating Scale and Scale for the Assessment of Negative Symptoms scores following amisulpride or amineptine treatment was twice as high as with placebo (p 〈 0.0001). The adverse event profile of amisulpride was similar to that of placebo except for endocrine symptoms in female patients; amineptine showed mainly events linked to psychic activation (insomnia, nervousness). Results show that amisulpride can improve symptoms of chronic depression in dysthymia.
Type of Medium:
Online Resource
ISSN:
0302-282X
,
1423-0224
Language:
English
Publisher:
S. Karger AG
Publication Date:
1999
detail.hit.zdb_id:
1483094-2
SSG:
5,2
SSG:
15,3
Permalink